Ki67 and proliferation in breast cancer

Journal of Clinical Pathology

Volumn 66, Issue 6, 2013, Pages 512-516

  Pathmanathan, Nirmala ^a,b,e   Balleine, Rosemary L ^c,d,e  

^a WESTMEAD HOSPITAL   (Australia)

^b Western Sydney Area Health Service   (Australia)

^c Western Sydney and Nepean Blue Mountains Local Health Districts ^*  (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

CANCER CELL; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CELL CYCLE REGULATION; CELL PROLIFERATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; SCORING SYSTEM; STAINING;

BREAST CANCER; BREAST PATHOLOGY; KI 67;

BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 84878344513     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201085     Document Type: Review

References (39)

1. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
2. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65.
3. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2012;11:174-83.
4. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-19.
5. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91. (Pubitemid 32176272)
6. Mook S, Van't Veer LJ, Rutgers EJ, et al. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 2011;103:585-97.
7. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
8. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44. (Pubitemid 47244357)
9. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74. (Pubitemid 32878711)
10. Sorlie T, Tibshirani R, Parker J, et al . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23. (Pubitemid 36842560)
11. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
12. Goldhirsch A, Wood WC, Coates AS. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
13. Coates AS, Colleoni M, Goldhirsch A. Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer? J Clin Oncol 2012;30:1260-3.
14. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
15. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
16. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
17. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
18. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-8.
19. Luporsi E, Andre F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2011;132:895-915.
20. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
21. Stuart-Harris R, Caldas C, Pinder SE, et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008;17:323-34.
22. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-13. (Pubitemid 46762956)
23. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation- associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513-22. (Pubitemid 23324910)
24. Kubbutat MH, Key G, Duchrow M. Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defi ned by the antibody Ki-67 (Ki-67 protein). J Clin Pathol 1994;47:524-8. (Pubitemid 24294015)
25. Zabaglo L, Salter J, Anderson H, et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 2010;63:800-4.
26. Yamamoto S, Ibusuki M, Yamamoto Y, et al. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer.
27. Tan PH, Bay BH, Yip G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005;18:374-81. (Pubitemid 40395356)
28. Sahebjam S, Aloyz R, Pilavdzic D, et al. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer 2011;105:1342-5.
29. Lehr HA, Rochat C, Schaper C, et al. Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas. Mod Pathol.
30. Pinhel IF, Macneill FA, Hills MJ, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2012;12:R76.
31. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-64.
32. Mohammed ZM, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012;106:383-8.
33. Balleine RL, Webster LR, Davis S, et al. Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 2008;14:8244-52.
34. Pathmanathan N, Albertini AF, Provan PJ, et al. Diagnostic evaluation of papillary lesions of the breast on core biopsy. Mod Pathol 2010;23:1021-8.
35. Pathmanathan N, Salisbury EL, Provan PJ, et al. A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast. Pathology 2010;42:28-36.
36. Aleskandarany MA, Rakha EA, Macmillan RD. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 2011;127:591-9.
37. Aleskandarany MA, Green AR, Benhasouna AA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 2012;14:R3.
38. Viale G, Giobbie-Hurder A, Regan MM, et al . Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569-75.
39. Penault-Llorca F, Abrial C, Raoelfils I, et al. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008;13:1235-45.